Bill
H 1240
Overview: H 1240, An Act relative to insulin access, Hearing scheduled for 10/01/2025 from 10:30 AM-01:00 PM in B-1, Introduced on February 27, 2025Purpose and Intent: The main goa
Overview: H 1240, An Act relative to insulin access, Hearing scheduled for 10/01/2025 from 10:30 AM-01:00 PM in B-1, Introduced on February 27, 2025
Purpose and Intent: The main goal of this bill is to improve access to affordable insulin for individuals who require it to manage their diabetes. The legislation aims to address the rising costs of insulin that have made it increasingly unaffordable for many patients.
Key Provisions:
- Requires health insurance plans to cover the cost of insulin with no deductible or copay for individuals with diabetes
- Establishes a state-run insulin assistance program to provide insulin at no cost to eligible low-income individuals
- Caps the maximum out-of-pocket cost for insulin at $50 per 30-day supply
Affected Parties and Impacts: This bill would primarily benefit individuals with diabetes who rely on insulin to manage their condition. It would help make insulin more accessible and affordable, particularly for those with limited financial resources. The legislation would also impact health insurance providers, who would be required to adjust their coverage policies to comply with the new requirements.
Procedural and Timeline Considerations: The bill is currently scheduled for a public hearing on October 1, 2025, where lawmakers and stakeholders will have the opportunity to provide input and feedback. If passed, the new insulin access provisions would likely take effect within the following year, providing relief to patients in need.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
